Anal Cancer Chemotherapy Algorithm

DPYD mutation analysis
Mutation analysis
NTRK



Recruitment to clinical trials should be considered where appropriate

Updated October 2025 (DW)

Neoadjuvant Colorectal Cancer Chemotherapy Algorithm



Updated October 2025 (DW)

Recruitment to clinical trials should be considered where appropriate

MMR/MSI status
DPYD mutation analysis

Adjuvant Colorectal Chemotherapy Algorithm



Consider adjuvant chemotherapy for rectal cancer based on pre-treatment clinical staging

Recruitment to clinical trials should be considered where appropriate

Updated October 2025 (DW)

Metastatic Colorectal Cancer Chemotherapy Algorithm

1. NICE TA439 (25/9/2017)
2. NICE TA668 (6/1/2021)
3. NICE TA709 (23/6/2021)
4. NICE TA716 (28/7/2021)
5. NICE TA405 (24/8/2016)
6. NICE TA866 (8/2/2023)
7. NICE TA11390 (28/8/2024)
8. NICE TA1065 (28/5/2025)
9. NICE TA11280 (23/7/2025)

MMR/MSI status
DPYD mutation analysis
Mutation analysis
RAS, BRAF
PIKC3A, HER2
NTRK

Metastatic Colorectal Cancer

Un-resectable metastatic disease

MMR proficient/MSI low

1st line

- Oxaliplatin or Irinotecan based combination chemotherapy
- Single agent Capecitabine or 5FU/Folinic Acid
- FOLFOXIRI
- Raltitrexed (alone or in combination with oxaliplatin)

RAS WT
Add EGFR antibody [1] to chemotherapy

2nd line

- Switch to alternative Irinotecan or Oxaliplatin combination therapy
- Consider referral for further mutation analysis/clinical trials

BRAF V600E mutation
Encorafenib +cetuximab [2]

3rd or subsequent

- Trifluridine/tipiracil [5] +/-bevacizumab[7]
- Fruquintinib[9]
- Regorafenib[6]
- Re-challenge with previous effective regime
- Consider referral for further mutation analysis/Clinical trials

MMR deficient/MSI high

- Pembrolizumab [3]
- Nivolumab + Ipilimumab[8]

- Nivolumab + Ipilimumab [4]

- Oxaliplatin or Irinotecan based combination chemotherapy
- Single agent Capecitabine Raltitrexed (alone or in combination with oxaliplatin)
- Consider referral for further mutation analysis/clinical trials

- Previously unused regimen
- Re-challenge with previous effective regime

Updated October 2025 (DW)

Recruitment to clinical trials should be considered where appropriate

Metastatic Colorectal Cancer Chemotherapy Algorithm



Updated October 2025 (DW)

Recruitment to clinical trials should be considered where appropriate